Literature DB >> 22954874

Virtual reality for smoking cessation: a case report.

Irene Pericot-Valverde1, Olaya García-Rodríguez, Marta Ferrer-García, Roberto Secades-Villa, José Gutiérrez-Maldonado.   

Abstract

This study presents a case report describing the use of Virtual Stop Smoking (VSS) program. The VSS includes a multicomponent behavioural approach and a Virtual Reality graded exposure technique. The subject was a 22-year-old female who smoked 20 cigarettes per day. Six weekly 90-minute sessions were conducted once a week over a 6-week period. Measures of efficacy included the number of cigarettes smoked, breath carbon monoxide levels, and self-reported subjective craving. The results obtained supported the efficacy of VSS for smoking cessation.

Entities:  

Mesh:

Year:  2012        PMID: 22954874

Source DB:  PubMed          Journal:  Stud Health Technol Inform        ISSN: 0926-9630


  4 in total

Review 1.  Review of Virtual Reality Treatment in Psychiatry: Evidence Versus Current Diffusion and Use.

Authors:  Matthew C Mishkind; Aaron M Norr; Andrea C Katz; Greg M Reger
Journal:  Curr Psychiatry Rep       Date:  2017-09-18       Impact factor: 5.285

Review 2.  The use of virtual reality in craving assessment and cue-exposure therapy in substance use disorders.

Authors:  Antoine Hone-Blanchet; Tobias Wensing; Shirley Fecteau
Journal:  Front Hum Neurosci       Date:  2014-10-17       Impact factor: 3.169

3.  Virtual Reality Smartphone-Based Intervention for Smoking Cessation: Pilot Randomized Controlled Trial on Initial Clinical Efficacy and Adherence.

Authors:  Emilio Goldenhersch; Johannes Thrul; Joaquín Ungaretti; Nicolas Rosencovich; Cristian Waitman; Marcelo Rodriguez Ceberio
Journal:  J Med Internet Res       Date:  2020-07-29       Impact factor: 5.428

4.  Evidence on Virtual Reality-Based Therapies for Psychiatric Disorders: Meta-Review of Meta-Analyses.

Authors:  Laura Dellazizzo; Stéphane Potvin; Mimosa Luigi; Alexandre Dumais
Journal:  J Med Internet Res       Date:  2020-08-19       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.